Memogain, formerly known as GLN-1062, is an acetylcholinesterase (AChE) inhibitor potentially for the treatment of Alzheimer's disease. Memogain, a pro-drug, liberates galantamine on cleavage by a carboxyesterase in the brain. Memogain has more than 15-fold higher bioavailability in the brain than the same doses of galantamine. In the brain, Memogain is enzymatically cleaved to galantamine, thereby regaining its pharmacological activity as a cholinergic enhancer. References: Bhattacharya S, Maelicke A, Montag D. Nasal Application of the Galantamine Pro-drug Memogain Slows Down Plaque Deposition and Ameliorates Behavior in 5X Familial Alzheimer's Disease Mice. J Alzheimers Dis. 2015;46(1):123-36. doi: 10.3233/JAD-142421. PubMed PMID: 25720404.

纯度：≥98%

CAS：224169-27-1